Care-Med Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 30-06-2024
- Paid Up Capital ₹ 0.99 M
as on 30-06-2024
- Company Age 25 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.36 Cr
as on 30-06-2024
- Revenue 4.55%
(FY 2020)
- Profit 208.52%
(FY 2020)
- Ebitda 23.99%
(FY 2020)
- Net Worth 27.90%
(FY 2020)
- Total Assets -9.46%
(FY 2020)
About Care-Med Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.99 M.
The company currently has active open charges totaling ₹1.36 Cr.
Subasri Subramanian and Subramanian Ramasamy serve as directors at the Company.
- CIN/LLPIN
U51397TN1999PTC042014
- Company No.
042014
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Mar 1999
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Kanchipuram, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Care-Med Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Subramanian Ramasamy  | Managing Director | 01-Oct-2001 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Subasri Subramanian | Director | 07-Jan-2013 | Current |
Financial Performance of Care-Med Pharmaceuticals.
Care-Med Pharmaceuticals Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 4.55% increase. The company also saw a substantial improvement in profitability, with a 208.52% increase in profit. The company's net worth Soared by an impressive increase of 27.9%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Care-Med Pharmaceuticals?
In 2020, Care-Med Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Tamilnad Mercantile Bank Limited Creation Date: 02 Aug 2021 | ₹0.57 M | Open |
Tamilnad Mercantile Bank Limited Creation Date: 09 Mar 2021 | ₹4.40 M | Open |
Tamilnad Mercantile Bank Limited Creation Date: 03 Jun 2020 | ₹1.13 M | Open |
How Many Employees Work at Care-Med Pharmaceuticals?
Unlock and access historical data on people associated with Care-Med Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Care-Med Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Care-Med Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
